Sat, May
7 New Articles

ContraVir Pharmaceuticals, Inc a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies announced that the company was awarded a $297,875 CAD research grant from the National Research Council in Canada through the Council's Industrial Research Assistance Program (IRAP).

Ardelyx, Inc. a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial evaluating RDX7675 in patients with hyperkalemia, a potentially life-threatening condition common in patients with cardiorenal disease.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.